Insider Selling: Bolt Biotherapeutics (NASDAQ:BOLT) COO Sells $22,194.00 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) COO Grant Yonehiro sold 6,850 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $22,194.00. Following the sale, the chief operating officer directly owned 17,269 shares in the company, valued at $55,951.56. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Grant Yonehiro also recently made the following trade(s):

• On Thursday, September 17th, Grant Yonehiro sold 4,909 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.32, for a total transaction of $16,297.88.
• On Wednesday, September 16th, Grant Yonehiro sold 1,417 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.77, for a total transaction of $5,342.09.

Bolt Biotherapeutics Stock Down 1.6%

Shares of BOLT stock opened at $3.65 on Thursday. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. The firm’s 50-day moving average is $3.82 and its 200-day moving average is $4.28. The stock has a market cap of $7.04 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. Bolt Biotherapeutics, Inc. has a 52-week low of $3.10 and a 52-week high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts predict that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BOLT shares. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Finally, Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $14.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its holdings in shares of Bolt Biotherapeutics by 40.3% during the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after acquiring an additional 22,200 shares during the period. T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $208,000. Finally, Nan Fung Group Holdings Ltd acquired a new stake in Bolt Biotherapeutics during the 2nd quarter worth approximately $19,250. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.